Veronica Indihar , MD

Cystic Fibrosis
Non CF bronchiectasis
 

Medical Degree: Universidad de Buenos Aires Buenos Aires, AR, 2002

Residency: John H. Stroger Hospital of Cook County Chicago, IL, 2007 (Internal Medicine)

Fellowship: University of Virginia Charlottesville, VA, 2011 (Pulmonary and Critical Care)

American Board of Internal Medicine (Pulmonary Disease) (Certification Date: 10-12-2010 ) - (Recertification Date: to 11-12-2021 )

American Board of Internal Medicine (Critical Care Medicine) (Certification Date: 11-09-2011 ) - (Recertification Date: to 01-01-2024 )

Critical Care Medicine

Cystic Fibrosis

Internal Medicine

Lung Disease

Pulmonary Disease

Airway Disorders

Bronchiectasis

Chronic Cough

Dyspnea

Histoplasmosis

Legionnaires' Disease (Legionellosis)

Pleurisy

Pneumonia

Respiration Disorders

Respiratory Syncytial Virus (RSV)

Respiratory Tract Disease

Respiratory Tract Infections

Shortness of Breath

Thoracic Disease

Tuberculosis

Whooping Cough (Pertussis)

Critical Care Medicine

Internal Medicine

Cystic fibrosis
Non CF bronchiectasis
General Pulmonary

8/1/2011 12:00:00 AM -7/15/0201 12:00:00 AM Assistant Professor Medicine -Pulmonary and Critical Care Division, University of Virginia , Charlottesville - Virginia

Grant: #CHMC_CFF Investigators:Indihar, Maria; Joseph, Patricia 07-01-2016 -12-31-2016 Cystic Fibrosis Foundation A CF C3N Care Model of the Future: Proposal for Piloting a Learning Health System Role:Collaborator $15,000.00 Active Level:Private Non-Profit

Grant: #INDIHA18Y6 Investigators:Indihar, Maria 01-01-2019 -12-31-2020 Cystic Fibrosis Foundation Improving research participation at UC Adult center Role:PI $26,260.00 Active Level:Private Non-Profit

Grant: #CC160-AD Investigators:Indihar, Maria 07-01-2019 -06-30-2020 Cystic Fibrosis Foundation CFF Center Grant Role:PI $112,020.00 Awarded Level:Private Non-Profit

Grant: #308189 / NAREN19R0 Investigators:Indihar, Maria 07-01-2019 -06-30-2020 Cystic Fibrosis Foundation Personalizing Cystic Fibrosis Research Translation, CCHMC RDP - Translational Studies Core Role:PI $5,417.00 Awarded Level:Private Non-Profit

Grant: #CCRX214-19 Investigators:Indihar, Maria 04-01-2019 -05-01-2022 Cystic Fibrosis Foundation Implementation of Outpatient Clinical Pharmacy Services: Award for a Pharmacist abd or/Pharmacy Technician Role:PI $112,320.00 Active Level:Private Non-Profit

Grant: #CCHMC_CFLN 2020 SEIDAB0-OS0001471 Investigators:Indihar, Maria 01-01-2020 -12-31-2020 Cystic Fibrosis Foundation CFLN Role:PI $30,464.00 Active Level:Private Non-Profit

Grant: #JOSEPH15Y0 - CFF Therapeutics Development Center (TDC) Investigators:Indihar, Maria; Joseph, Patricia 04-01-2020 -03-31-2021 Cystic Fibrosis Foundation TDN - Cystic Fibrosis Foundatipn Therapeutics Development Center Role:PI $45,770.40 Active Level:Private Non-Profit

Grant: #JOSEPH15Y4 Investigators:Indihar, Maria; Joseph, Patricia 04-01-2020 -03-31-2021 Cystic Fibrosis Foundation CFF ARC Grant Role:PI $18,146.00 Active Level:Private Non-Profit

Grant: #Mayflowers Study Site Subcontract Investigators:Indihar, Maria; Warshak, Carri 04-01-2021 -03-31-2025 Cystic Fibrosis Foundation MAYFLOWERS-OB-20 Role:PI 59841.86 Hold Level:Non Profit

Grant: #AP-PA02-101 Investigators:Indihar, Maria 12-01-2021 -11-30-2024 Armata Pharmaceuticals A PHASE 1B/2A, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AP-PA02 MULTIPHAGE THERAPEUTIC CANDIDATE Role:PI 278698.32 Hold Level:Industry

Grant: #INDIHA22Y0 Investigators:Indihar, Maria; Khawar, Muhammad 04-01-2022 -03-31-2023 Cystic Fibrosis Foundation CFF TDN Role:PI 71724.00 Hold Level:Non Profit

Grant: #BI: 1397-0012 Investigators:Indihar, Maria 02-01-2022 -02-01-2025 Boehringer Ingelheim International GmbH A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis Role:PI 323670.16 Hold Level:Industry

Grant: #M21-432 Investigators:Indihar, Maria 05-01-2022 -04-30-2025 AbbVie, Inc. A Phase 4 Study to Assess Symptoms of Exocrine Pancreatic Insufficiency in Subjects with Cystic Fibrosis or Chronic Pancreatitis Treated with Creon (Pancrelipase) with an Alternate Source of Active Role:PI 70226.51 Hold Level:Industry

Investigators:Indihar, Maria 12-01-2022 -11-30-2024 Cystic Fibrosis Foundation Assessing accuracy and reliability of self-obtained respiratory cultures, and implementation of home respiratory cultures as part of clinical care Role:PI 26880.01 Hold Level:Non Profit

Grant: #VX21-522-001 Investigators:Indihar, Maria 04-24-2023 -04-30-2026 Vertex Pharmaceuticals Incorporated A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Role:PI 152029.74 Hold Level:Industry

Investigators:Indihar, Maria -06-30-2026 Cystic Fibrosis Foundation Strength and Muscle Related Outcomes for Nutrition and Lung Function in Cystic Fibrosis - STRONG CF Role:PI 0.00 Hold Level:Non Profit

Grant: #UWSC14685 / R01NR020470 Investigators:Drosatos, Konstantinos; Indihar, Maria 04-19-2023 -01-31-2028 University of Washington Role of JNK and BNP in Septic Hypotension Role:Collaborator 18543.00 Hold Level:Higher Education

Grant: #STOP360-Indihar Investigators:Indihar, Maria; Khawar, Muhammad 10-01-2023 -03-31-2026 Cystic Fibrosis Foundation Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Role:PI 66233.66 Hold Level:Non Profit

Grant: #006369QI323 Investigators:Indihar, Maria; Oder, Angela 01-01-2024 -12-31-2025 Cystic Fibrosis Foundation CFLN Role:PI 55960.00 Hold Level:Non Profit

Grant: #ANG003-22-101 Investigators:Indihar, Maria 12-25-2023 -12-24-2026 Anagram Therapeutics Inc. A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF ANG003 IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS Role:PI 113542.75 Active Level:Industry

Grant: #AP-PA02-201 Investigators:Indihar, M. Veronica 02-29-2024 -02-28-2027 Armata Pharmaceuticals A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cyst Role:PI 241740.36 Hold Level:Industry

Grant: #1397-0013 Investigators:Indihar, M. Veronica 03-20-2024 -03-19-2027 Boehringer Ingelheim International GmbH "A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus Role:PI 172504.25 Awarded Level:Industry

Grant: #1397-0017 Investigators:Indihar, M. Veronica 03-27-2024 -03-26-2027 Boehringer Ingelheim International GmbH A randomised double-blind parallel group roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 qd (Part A) followed by open label long-term safety assessment (Part Role:PI 261706.00 Hold Level:Industry

Published Abstracts

Indihar,MV; Joseph,PM, Trapnell, B; Burns,LA;Meyers,M; Major,T; Montag,K (2016. ) Early experience initiating Orkambi therapy in adults Cystic Fibrosis patients .[Abstract]Pediatric Pulmonology - the 30th Annual North American Cystic Fibrosis Conference , 50 ,286

Peer Reviewed Publications

Mark H.Eckman,Elizabeth J.Kopras, Karen Montag, Lari P.Kirby, Lisa Burns, Veronica Indihar, Patricia Joseph (BAD DATE. ) Shared Decision- Making Tool for Self- Management of Home Therapies for patients with Cystic Fibrosis .MDM Policy & Practice, , 2 (1 ) ,

Academic - Department of Internal Medicine, Medical Sciences Building
231 Albert Sabin Way, ML 0564
Cincinnati  Ohio, 45267
Phone: Phone: 513-558-4831
indihama@uc.edu